Endpoints News 生物医药· Reynald Castaneda·· 2 天前AI 评分33
辉瑞通过与Starna Therapeutics授权合作进入in vivo CAR-T领域
Pfizer gets into in vivo CAR-T through licensing deal with Starna Therapeutics
AI 导读
辉瑞支付3.3亿美元预付款,获得Starna Therapeutics授权,正式进入in vivo CAR-T领域。该交易授予辉瑞大中华区以外地区的独家权益。
正文
Pfizer is entering the in vivo CAR-T race, paying $330 million upfront to Starna Therapeutics. The deal gives Pfizer exclusive rights outside of Greater China …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news